<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ten patients with high-risk <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) relapsing early (&lt; 1 year, n = 8) or late (&gt; or = 1 year, n = 2) after allogeneic transplantation were treated with cytoreductive chemotherapy followed by unmanipulated peripheral blood stem cell transplantation (PBSCT) from related (n = 3) and unrelated donors (n = 7) </plain></SENT>
<SENT sid="1" pm="."><plain>In order to enhance the graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effect, patients received no <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis and granulocyte-macrophage colony-stimulating factor (GM-CSF) was given at a dose of 60 micrograms/m2 after transplant </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD grade I-IV was seen in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Eight out of ten patients achieved complete remission: one out of two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and late relapse is in good condition with limited <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD more than 1 year after the second PBSCT </plain></SENT>
<SENT sid="4" pm="."><plain>The other patient died on day +171 after the second PBSCT from <z:e sem="disease" ids="C0948691" disease_type="Disease or Syndrome" abbrv="">cerebral aspergillosis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>One patient with <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> <z:mp ids='MP_0005481'>CML</z:mp> achieved molecular remission but died +330 days after the second PBSCT because of <z:mp ids='MP_0001915'>intracranial bleeding</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Of the remaining five patients, three died of infectious complications on days +36, +70, and +27, one patient died with extramedullary relapse on day +35, and one from multi-organ failure in association with <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD on day +32 after the second PBSCT </plain></SENT>
<SENT sid="7" pm="."><plain>Two out of ten showed progressive disease and died on days +30 and +90, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Although several patients achieved complete remission, the high risk of GVHD and treatment-related mortality should be kept in mind, especially when a second transplant is considered during a period of less than 12 months after the first procedure </plain></SENT>
<SENT sid="9" pm="."><plain>Monitoring of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> might predict relapse thus preventing high doses of cytotoxic drugs for reconditioning </plain></SENT>
<SENT sid="10" pm="."><plain>The potential of GM-CSF to enhance the graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> reactivity after cytoreductive therapy for allogeneic transplantation warrants further investigation </plain></SENT>
</text></document>